Efficacy and Safety of Lapatinib and Trastuzumab for HER2-Positive Breast Cancer: a Systematic Review and Meta-Analysis of Randomised Controlled Trials

Based on the evidence from this study, the addition of lapatinib to trastuzumab can significantly improve pathological complete response rate, event-free survival, and overall survival with a tolerated toxicity in patients with HER2-positive breast cancer.

Efficacy and Safety of Lapatinib and Trastuzumab for HER2-Positive Breast Cancer: a Systematic Review and Meta-Analysis of Randomised Controlled Trials

Videos

Perspectives on the Collaborative Management of HER2-Positive Breast Cancer

Advertisement

In The News

The ASCO Post

Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care

MedicalXpress

Researchers Discover Key to Drug Resistance in Common Breast Cancer Treatment

OncLive

Age and Subtype Impact Outcomes More Than Surgical Extent in Breast Cancer

OncLive

Neoadjuvant Therapy Fundamental in Triple-Negative and HER2-Positive Breast Cancer

BreastCancer.org

Kisqali Approved by FDA to Treat Hormone-Receptor-Positive, Advanced-Stage Disease

View all >

In The Literature

JAMA Oncol

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial

Eur J Cancer

Long-term Outcome of the REMAGUS 02 Trial, a Multicenter Randomised Phase II Trial in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy With or Without Celecoxib or Trastuzumab According to HER2 Status

JAMA Oncol

Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study

BMC Cancer

Development of a Test that Measures Real-Time HER2 Signaling Function in Live Breast Cancer Cell Lines and Primary Cells

Ann Surg Oncol

Results of a Phase Ib Trial of Combination Immunotherapy With a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients

View all >